534 related articles for article (PubMed ID: 28025384)
21. Immune checkpoint inhibitors and endocrine side effects, a narrative review.
Agrawal L; Bacal A; Jain S; Singh V; Emanuele N; Emanuele M; Meah F
Postgrad Med; 2020 Mar; 132(2):206-214. PubMed ID: 31876444
[TBL] [Abstract][Full Text] [Related]
22. Cancer immunology and melanoma immunotherapy.
Linck RDM; Costa RLP; Garicochea B
An Bras Dermatol; 2017; 92(6):830-835. PubMed ID: 29364441
[TBL] [Abstract][Full Text] [Related]
23. Crystallographic approaches to study the interaction modes of PD-1- and CTLA-4-blocking antibodies.
Nomura N; Nomura Y; Sato Y; Iwata S
Methods Enzymol; 2019; 629():383-399. PubMed ID: 31727250
[TBL] [Abstract][Full Text] [Related]
24. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
Sibaud V
Am J Clin Dermatol; 2018 Jun; 19(3):345-361. PubMed ID: 29256113
[TBL] [Abstract][Full Text] [Related]
25. Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology.
Lee HT; Lee SH; Heo YS
Molecules; 2019 Mar; 24(6):. PubMed ID: 30917623
[TBL] [Abstract][Full Text] [Related]
26. Immune checkpoint blockade therapy.
Wieder T; Eigentler T; Brenner E; Röcken M
J Allergy Clin Immunol; 2018 Nov; 142(5):1403-1414. PubMed ID: 29596939
[TBL] [Abstract][Full Text] [Related]
27. [Hepatic and digestive adverse events of immune checkpoint inhibitors (anti-CTLA-4 and, anti-PD-1/PD-L1): A clinico-pathological review].
Papouin B; Mussini C; De Martin E; Guettier C
Ann Pathol; 2018 Dec; 38(6):338-351. PubMed ID: 30143243
[TBL] [Abstract][Full Text] [Related]
28. Predictors of immunotherapy-induced immune-related adverse events.
Kartolo A; Sattar J; Sahai V; Baetz T; Lakoff JM
Curr Oncol; 2018 Oct; 25(5):e403-e410. PubMed ID: 30464691
[TBL] [Abstract][Full Text] [Related]
29. Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient.
Herz S; Höfer T; Papapanagiotou M; Leyh JC; Meyenburg S; Schadendorf D; Ugurel S; Roesch A; Livingstone E; Schilling B; Franklin C
Eur J Cancer; 2016 Nov; 67():66-72. PubMed ID: 27614165
[TBL] [Abstract][Full Text] [Related]
30. Immune checkpoint inhibitors associated granulomatous small vessel vasculitis accompanied with tubulointerstitial nephritis: a case report.
Tominaga K; Takeuchi K; Takakuma S; Sakamoto E; Hatanaka S; Kajimoto Y; Toda E; Terasaki Y; Kunugi S; Terasaki M; Shimizu A
BMC Nephrol; 2023 Mar; 24(1):48. PubMed ID: 36894873
[TBL] [Abstract][Full Text] [Related]
31. Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy-Report of 2 patients.
Tetzlaff MT; Jazaeri AA; Torres-Cabala CA; Korivi BR; Landon GA; Nagarajan P; Choksi A; Chen L; Uemura M; Aung PP; Diab A; Sharma P; Davies MA; Amaria R; Prieto VG; Curry JL
J Cutan Pathol; 2017 Dec; 44(12):1080-1086. PubMed ID: 28901560
[TBL] [Abstract][Full Text] [Related]
32. Checkpoint Blockade for the Treatment of Advanced Melanoma.
Callahan MK; Flaherty CR; Postow MA
Cancer Treat Res; 2016; 167():231-50. PubMed ID: 26601865
[TBL] [Abstract][Full Text] [Related]
33. Review of Immune Therapies Targeting Ovarian Cancer.
Fan CA; Reader J; Roque DM
Curr Treat Options Oncol; 2018 Nov; 19(12):74. PubMed ID: 30430276
[TBL] [Abstract][Full Text] [Related]
34. Endocrine, Sexual Function, and Infertility Side Effects of Immune Checkpoint Inhibitor Therapy for Genitourinary Cancers.
Sood A; Cole D; Abdollah F; Eilender B; Roumayah Z; Deebajah M; Dabaja A; Alanee S
Curr Urol Rep; 2018 Jul; 19(9):68. PubMed ID: 29971696
[TBL] [Abstract][Full Text] [Related]
35. Immune checkpoints and cancer development: Therapeutic implications and future directions.
Mehdizadeh S; Bayatipoor H; Pashangzadeh S; Jafarpour R; Shojaei Z; Motallebnezhad M
Pathol Res Pract; 2021 Jul; 223():153485. PubMed ID: 34022684
[TBL] [Abstract][Full Text] [Related]
36. Ipilimumab-induced renal granulomatous arteritis: a case report.
Lemoine M; Dilly B; Curie A; Hébert V; Laurent C; Hanoy M; Grangé S; Guerrot D; François A; Bertrand D
BMC Nephrol; 2019 Oct; 20(1):366. PubMed ID: 31604452
[TBL] [Abstract][Full Text] [Related]
37. Uveitis in Patients Treated with CTLA-4 and PD-1 Checkpoint Blockade Inhibition.
Sun MM; Levinson RD; Filipowicz A; Anesi S; Kaplan HJ; Wang W; Goldstein DA; Gangaputra S; Swan RT; Sen HN; Gordon LK
Ocul Immunol Inflamm; 2020; 28(2):217-227. PubMed ID: 30821569
[No Abstract] [Full Text] [Related]
38. Editorial: Immune Checkpoint Molecules and Cancer Immunotherapy.
Bazhin AV; Amedei A; Karakhanova S
Front Immunol; 2018; 9():2878. PubMed ID: 30568661
[No Abstract] [Full Text] [Related]
39. Development of Cancer Immunotherapy Targeting the PD-1 Pathway.
Kamimura N; Wolf AM; Iwai Y
J Nippon Med Sch; 2019; 86(1):10-14. PubMed ID: 30918149
[TBL] [Abstract][Full Text] [Related]
40. Molecular Pathways: Immune Checkpoint Antibodies and their Toxicities.
Cousin S; Italiano A
Clin Cancer Res; 2016 Sep; 22(18):4550-5. PubMed ID: 27435397
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]